食品和药物管理局批准梅里洛,一种快速反应的胰岛素生物相似,以促进糖尿病治疗的获得。 FDA approves Merilog, a rapid-acting insulin biosimilar, to boost diabetes treatment access.

食品和药物管理局批准了梅里洛病,这是第一个快速反应的胰岛素生物类似物,用于治疗成人和儿童糖尿病。 The FDA has approved Merilog, the first rapid-acting insulin biosimilar, for treating diabetes in adults and children. 由Sanofi-Aventis开发的Merilog与Novolog非常相似,可装在预装笔和小瓶中。 Developed by Sanofi-Aventis, Merilog is highly similar to Novolog and is available in a prefilled pen and vial. 这是对胰岛素生物相似物的第三次批准,目的是增加3 800多万糖尿病美国人获得安全有效的糖尿病治疗的机会。 This approval, the third for insulin biosimilars, aims to increase access to safe and effective diabetes treatments for the over 38 million Americans with diabetes.